Anti-inflammatory, but not osteoprotective, effect of the TRAF6/CD40 inhibitor 6877002 in rodent models of local and systemic osteolysis
In conclusion, TRAF6 inhibitors may be of value in the management of the inflammatory component of bone disorders, but may not offer protection against local or systemic bone loss, unless combined with anti-resorptive therapy such as bisphosphonates.PMID:34896056 | DOI:10.1016/j.bcp.2021.114869
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Silvia Marino Nicole Hannemann Ryan T Bishop Feier Zeng Giovana Carrasco Sandrine Meurisse Boya Li Antonia Sophocleous Anna Sparatore Tobias Baeuerle Slobodan Vukicevic Marielle Auberval Patrick Mollat Aline Bozec Aymen I Idris Source Type: research
More News: Arthritis | Cancer | Cancer & Oncology | Drugs & Pharmacology | Oral Cancer | Rheumatology